Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

40.84 UNCHANGED
Streaming Delayed Price Updated: 1:18 PM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,948,637
Open 40.85
Bid (Size) 40.83 (7,700)
Ask (Size) 40.84 (3,400)
Prev. Close 40.84
Today's Range 40.78 - 40.86
52wk Range 16.10 - 40.87
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire

Performance

YTD
+57.9%
+57.9%
1 Month
+116.4%
+116.4%
3 Month
+76.0%
+76.0%
6 Month
+69.2%
+69.2%
1 Year
+111.3%
+111.3%

More News

Read More
News headline image
Why Biogen Stock Got Mashed on Monday ↗
Via The Motley Fool
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
Via MarketMinute
Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate ↗
Via Chartmill
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Q4 2025 Earnings Beat Amid Mixed Revenue Results ↗
Via Chartmill
Topics Earnings
News headline image
The Coiled Spring: Why Small-Caps are Poised for a Generational Productivity-Led Surge
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, EQH, VYNE are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
Via MarketMinute
News headline image
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
From Kahn Swick & Foti
Via Business Wire
News headline image
Why Biogen Stock Sank While the Market Soared on Thursday ↗
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, BIRD, WBD are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
Via MarketMinute
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
Via AB Newswire
These stocks are making the most noise in today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
Discover the top movers in Tuesday's pre-market session. ↗
Via Chartmill
News headline image
APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis (APLS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?
Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market
What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 40.84
When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 04/14/26 01:18 PM ET
What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 4.76B
How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
Apellis Pharmaceuticals, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.